i2o Therapeutics has developed disruptive ionic liquid technology to enable oral delivery of biologicsctschensui2022-12-02T07:07:12+00:00 Project Description i2o Therapeutics has developed disruptive ionic liquid technology for next generation of oral biologics. Project Details Categories: Commercial Project URL: View Project Copyright: Theme-Fusion Related Projects Aqualung is a Tucson, AZ and Jupiter, FL -based biotech company to provide an immune-focused biologic platform for serious inflammatory and fibrotic disorders. February 22nd, 2023 | 0 Comments BBy is revolutionizing the way hospitals manage, store and deliver breast milk to infants in the most need February 13th, 2015 | 0 Comments Curbside is delivering software that makes it easy for clinicians to consistently deliver best practice clinical care February 13th, 2015 | 0 Comments Epion Therapeutics is developing a best in class minimally- invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. September 12th, 2025 | 0 Comments Kayothera is developing first-in-class small molecule immunotherapies to treat solid cancers February 13th, 2015 | 0 Comments